Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Nimotuzumab in Resectable ESCC
NCT02272699Phase 3Withdrawn
- Sponsor
- Peking University
- Start
- Nov 2014
- Primary completion
- Dec 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nimotuzumab in Esophageal Squamous Cell Carcinoma (ESCC) (3 arms), sponsored by Peking University. Primary endpoint: Disease-free survival at 2 years. Planned start Nov 2014; status: withdrawn.
02
Drugs
nimotuzumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT02272699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02272699.